Search

Your search keyword '"Cloven, N.G."' showing total 7 results
Start Over Author "Cloven, N.G."
7 results on '"Cloven, N.G."'

1. LBA32 A randomized, phase II, dose optimization of gotistobart, a pH-sensitive anti-CTLA-4, in combination with standard dose pembrolizumab in platinum-resistant recurrent ovarian cancer: Safety, efficacy and dose optimization (PRESERVE-004/GOG-3081)

Author

Barlin, J.N., Lim, P.C., Thomes Pepin, J., Hopp, E.E., Cloven, N.G., Lee, C., Eshed, H.D., Black, D., Cottrill, H.M., Hand, L., O'Malley, D.M., Chuang, L.T., Willmott, L., Chisamore, M., Shpyro, S., Durbin, J., Zheng, P., Liu, Y., and Monk, B.J.

Published
2024
Full Text
View/download PDF

3. 810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial

Author

Pothuri, B., primary, Han, S., additional, Chase, D., additional, Heitz, F., additional, Burger, R., additional, Gaba, L., additional, Van Le, L., additional, Guerra, E., additional, Bender, D., additional, Korach, J., additional, Cloven, N.G., additional, Follana, P., additional, Baurain, J-F., additional, Pisano, C., additional, Peen, U., additional, Maenpaa, J., additional, Bacqué, E., additional, Li, Y., additional, Martín, A. González, additional, and Monk, B.J., additional

Published
2020
Full Text
View/download PDF

4. 818P Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study

Author

Okamoto, A., primary, Fleming, G., additional, Bookman, M., additional, Brady, M.F., additional, Swisher, E.M., additional, Steffensen, K.D., additional, Cloven, N.G., additional, Enomoto, T., additional, O'Malley, D.M., additional, Van Le, L., additional, Tewari, K.S., additional, Barlin, J.N., additional, Bradley, W., additional, Moore, K.N., additional, Chan, J., additional, Wu, M., additional, Hashiba, H., additional, Dinh, M.H., additional, Coleman, R.L., additional, and Aghajanian, C., additional

Published
2020
Full Text
View/download PDF

5. QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset

Author

Moore, K.N., primary, Secord, A.A., additional, Geller, M., additional, Miller, D.S., additional, Cloven, N.G., additional, Fleming, G.F., additional, Wahner Hendrickson, A.E., additional, Azodi, M., additional, DiSilvestro, P., additional, Oza, A., additional, Cristea, M., additional, Berek, J.S., additional, Chan, J.K., additional, Rimel, B.J., additional, Li, Y., additional, Luptakova, K., additional, Clark, R., additional, Matulonis, U.A., additional, and Monk, B.J., additional

Published
2018
Full Text
View/download PDF

6. Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer

Author

Matulonis, U.A., Monk, B.J., Secord, A.A., Geller, M.A., Miller, D.S., Cloven, N.G., Fleming, G.F., Hendrickson, A.E. Wahner, Azodi, M., DiSilvestro, P.A., Oza, A.M., Cristea, M., Berek, J.S., Chan, J.K., Li, Y., Luptakova, K., Hazard, S.J., and Moore, K.N.

Published
2019
Full Text
View/download PDF

7. 944P - QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset

Author

Moore, K.N., Secord, A.A., Geller, M., Miller, D.S., Cloven, N.G., Fleming, G.F., Wahner Hendrickson, A.E., Azodi, M., DiSilvestro, P., Oza, A., Cristea, M., Berek, J.S., Chan, J.K., Rimel, B.J., Li, Y., Luptakova, K., Clark, R., Matulonis, U.A., and Monk, B.J.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results